The symptoms can include nerve pain, emotional numbness and sexual dysfunction and can last for years after stopping the ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Although anti-calcitonin gene-related peptides are safe and efficacious for adolescents with chronic migraine, access to treatment is often subject to extended insurance authorization delays, ...

Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

These 2025 high school graduates can look back with pride and forward with confidence, as we salute them in our annual ...

Lilly’s FRα targeting ADC is composed of an Fc-silent, FRα specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker.

Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety ...

INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156 ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.